Amgen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Amgen Earnings Reaction Close To All-Time Highs!

AI-generated analysis

📈 Amgen reported Q2 2012 revenue of $4.5 billion, representing a 13% year-over-year gain.

💰 Adjusted earnings per share rose 34% to $1.83, significantly beating the consensus estimate of $1.54.

🚀 The company raised its full-year 2012 revenue guidance to $16.9-$17.2 billion and EPS guidance to $6.20-$6.35.

💊 Amgen recognized $206 million in other revenues from a modified agreement with Takeda for Motesanib development rights.

📉 The company generated approximately $2.2 billion in free cash flow during the quarter.

🔬 Four Phase 2 studies for AMG 145 completed successfully, with Phase 3 trials planned to start in early 2013.

📊 Shares closed up 0.7% at $79.29 and traded above $80 after the earnings announcement.

🏦 Amgen maintains a long-term debt balance of approximately $22 billion.

📉 Share repurchase activity has reduced the share count, contributing to higher adjusted EPS.

👀 Analyst price targets are expected to be raised following the strong performance and beat.

Bullish Signals
  • Revenue grew 13% year-over-year to $4.5 billion, demonstrating strong top-line momentum.
  • Adjusted earnings per share surged 34% to $1.83, significantly exceeding analyst expectations of $1.54.
  • Full-year revenue guidance was raised to a range of $16.9-$17.2 billion, indicating confidence in future growth.
  • EPS guidance was increased to $6.20-$6.35, placing the company above the consensus estimate of $6.15.
  • Strong portfolio performance drove 8% product sales growth across all therapeutic areas.
  • Successful completion of four Phase 2 studies for AMG 145 paves the way for Phase 3 development in early 2013.
  • Generated robust free cash flow of approximately $2.2 billion, providing financial flexibility.
  • Stock price rallied to trade above $80, approaching the 52-week high of $80.25 following the news.
  • Share repurchase program has effectively lowered share count, enhancing per-share metrics.
  • Analyst consensus price target is expected to be raised from nearly $76.00 based on these results.
Risk Factors
  • The company carries a significant long-term debt balance of approximately $22 billion.
Full Analysis
Amgen Inc. reported second-quarter 2012 financial results showing a 13% revenue increase to $4.5 billion and adjusted earnings rising 34% to $1.83 per share, significantly beating Thomson Reuters estimates of $1.54 EPS and $4.08 billion in revenue. The company raised its full-year 2012 guidance for total revenue to between $16.9 billion and $17.2 billion, with adjusted earnings targets set at $6.20 to $6.35 per share. This new range places the company's expectations above the consensus estimates of approximately $6.15 EPS and $16.4 billion in revenue. Amgen attributed 8% product sales growth to strong portfolio performance and recognized $206 million in other revenues from a modified agreement with Takeda regarding Motesanib development rights. The company generated approximately $2.2 billion in free cash flow for the quarter while maintaining a long-term debt balance of nearly $22 billion. Looking ahead, Amgen announced that four Phase 2 studies for AMG 145 have successfully completed, with plans to initiate Phase 3 development in early 2013. Following the earnings release, shares closed up 0.7% at $79.29 and traded higher than $80, approaching their 52-week high of $80.25. Analysts are expected to raise price targets following the strong results, as the stock outperformed the consensus target of nearly $76.00. The company's share repurchase activity has also contributed to a lower share count, further supporting adjusted earnings per share growth.